ArticleHuman vaccines & immunotherapeutics2025
Real-world study: Analysis of post-marketing safety for recombinant zoster vaccine in Shandong, China.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the safety of the recombinant zoster vaccine (RZV) after its marketing in Shandong, China, using adverse events following immunization (AEFI) data. AEFI reports for RZV were collected by the Chinese National AEFI Information Management System (CNAEFIs) between July 2020 and September 2024. In total, 279 AEFI cases were found after administering 145,865 doses of RZV, resulting in an AEFI rate of 19.13 per 10,000 doses. Of these cases, 274 (98.21%) were attributed to vaccine-related reactions, while 5 (1.79%) were coincidental events. The reporting rate was higher for the first dose (24.22 per 10,000) than that for the second (13.20 per 10,000), and the reporting rate was higher in females (21.71 per 10,000) than in males (14.31 per 10,000). Fever, localized redness/induration accounted for 92.83% of the cases after administering RZV. Three positive signals, zoster, vestibular neuritis, and moderate fever, were detected using data mining. No new adverse reactions were identified, and 97.49% of AEFI cases were mild, indicating that the post-marketing safety profile of RZV remains within the expected limit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.